DFDA

Hydralazine (IV)

Treatment for Maternal Hypertensive Disorders

Typical Dosage: 5 mg IV bolus, then 5-10 mg every 20-30 min

Effectiveness
85%
Safety Score
68%
Clinical Trials
50
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg IV bolus, then 5-10 mg every 20-30 min
Time to Effect
10-20 minutes (IV)
Treatment Duration
Short-term, acute management
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,200
Side Effect Mgmt:$0
Total Annual:$1,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
0.2
Hydralazine (IV) Outcomes

for Maternal Hypertensive Disorders

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Common Side Effects
Headache
+15%
Flushing
+10%
Tachycardia
+7%
Nausea
+7%
Hypotension
+5%

Sources:

nih.gov
researchgate.net
mdpi.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov